Drug Trial Radar · NCT05075824
A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)
Last checked: Nov 20, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
95
Actual
Start
Mar 9, 2022
Primary completion
Jun 11, 2025
Study completion Apr 9, 2026
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Oct 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the efficacy, safety and pharmacokinetics of crovalimab compared with placebo as adjunct therapy in the prevention of VOEs in participants with SCD.
Conditions
- Sickle Cell Disease
Interventions
CrovalimabDrug
Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 kg and 100 kg) or 1500 mg IV (for participants with body weight \>= 100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, crovalimab will be administered at a dose of 680 mg SC (for participants with body weight between 40 kg and 100 kg) or 1020 mg SC (for participants with body weight \>= 100 kg). Dosing schedule will be as per Arm Description.
PlaceboDrug
Matching Placebo will be administered with the same dosing schedule and equivalent IV and SC volume as weight-based Crovalimab.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized rate of medical facility VOEs (AVR)Time frame: Baseline up to Week 49
Locations
27 sites in 11 countries. Site status is shown where the registry gives one.
Children's Hospital of Michigan
Detroit, Michigan
Mississippi Center for Advanced Medicine
Madison, Mississippi
Icahn School of Medicine at Mount Sinai
New York, New York
East Carolina University
Greenville, North Carolina
HEMORIO
Rio de Janeiro, Brazil
Hospital Samaritano
São Paulo, Brazil
Hospital Sao Rafael - HSR
Salvador, Estado de Bahia, Brazil
Hospital das Clinicas - UFRGS
Porto Alegre, Rio Grande do Sul, Brazil
UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu
Botucatu, São Paulo, Brazil
Hospital das Clínicas Faculdades Médicas de Ribeirão Preto
Ribeirão Preto, São Paulo, Brazil
Hospital de Base de Sao Jose do Rio Preto
São José do Rio Preto, São Paulo, Brazil
Beneficencia Portuguesa de Sao Paulo
São Paulo, São Paulo, Brazil
CHU Henri Mondor
Créteil, France
Università degli Studi della Campania Luigi Vanvitelli
Naples, Campania, Italy
Azienda Ospedaliera di Verona-Policlinico G.B. Rossi
Verona, Veneto, Italy
International Cancer Institute (ICI)
Eldoret, Kenya
Gertrude's Children Hospital
Nairobi, Kenya
Hopital Nini
Tripoli, Lebanon
Amsterdam UMC Location VUMC
Amsterdam, Netherlands
Charlotte Maxeke Johannesburg Hospital
Johannesburg, South Africa
Hospital General Univ. Gregorio Maranon
Madrid, Spain
Hospital Universitario Miguel Servet
Zaragoza, Spain
Adana Acibadem Hospital; Pediatric Hematology
Adana, Turkey (Türkiye)
Cukurova University Medical Faculty Balcali Hospital
Adana, Turkey (Türkiye)
Mersin Universitesi Tip Fakultesi Hastanesi
Mersin, Turkey (Türkiye)
Central Middlesex Hospital
London, United Kingdom
Hammersmith Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.